This is a working overview of MC1R, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
== Distribution == This species has long been known throughout the world as a common pest, so its origins are uncertain, but it may have originated in Sub-Saharan Africa. It moved into Europe long ago, and was likely introduced to North America from there.
== Classical qualitative organic analysis == Classical qualitative organic analysis usually involves reacting an unknown sample with various reagents; a positive test usually involves a change in appearance — color, precipitation, etc. These tests may be extended to give sub-gram scale products. These products may be purified by recrystallization, and their melting points taken. An example is the formation of 2,4-dinitrophenylhydrazones from ketones and 2,4-dinitrophenylhydrazine. By consulting an appropriate reference table such as in Vogel's, the identity of the starting material may be deduced. The use of derivatives has traditionally been used to determine or confirm the identity of an unknown substance. However, due to the wide range of chemical compounds now known, it is unrealistic for these tables to be exhaustive. Modern spectroscopic and spectrometric techniques have made this technique obsolete for all but pedagogical purposes.
It was only during the 1980s that a consensus among researchers was reached that these vessels can preserve as much as 30 to 40% of coronary blood flow to an otherwise-occluded blood vessel, and, while not capable of preventing ischemia in the event of high-output exercise, can nevertheless maintain aortic, pulmonic, and atrial blood pressure, redirect ST elevation into less serious ST depression in ischemia, and prevent infarction and symptoms of infarction, even in the case of complete left main coronary artery stenosis. The native collaterals are small vessels, with a narrow endothelial lining, a layer or two of smooth muscle, and a variable amount of elastic tissue. They are rarely if ever observed during angiography in the absence of severe ischemia (vessels less than 200 micrometers are not visible, generally), and only coronary stenosis, anemia, and exercise have experimentally been shown to cause transformation. Most observers agree that a 90% occlusion is necessary to bring about transformation in the absence of other factors, though a recent article suggests that they may appear as a result of coronary spasm in the absence of total occlusion (see below). Within ninety seconds of occlusion, the pressure gradient between the segment of the coronary vessel distal to the occlusion and the incipient collateral vessel precipitates damage to the internal elastic lamina, provoking an inflammatory response; monocytes and polycytes migrate to the vascular wall, which has, as a result of the occlusion, become permeable to the blood's cellular components.
====== The balkan route ====== The Balkan route remains the principal corridor for trafficking illegal opiates, primarily heroin, from Afghanistan to Western and Central Europe, with criminal networks-often highly organized and adaptable-leveraging both legal businesses and corruption to facilitate the smuggling, storage, and distribution of drugs. These groups generate enormous illicit profits, with the annual gross income from drug trafficking along the Balkan route estimated between $13.9 and $21.4 billion from 2019 to 2022, of which up to half is illegally moved across borders through complex financial flows that include shell companies, cryptocurrencies, and informal systems like hawala. The majority of these profits, around 90 percent, come from opiates, and the scale of this income rivals or exceeds the GDP of several countries along the route. The movement of these illicit funds not only sustains and expands drug trafficking operations but also undermines economic stability and governance in affected countries, making the Balkan route a persistent and multifaceted challenge for law enforcement and policymakers in the region.
Understanding the igneous petrology of monazite is important to be able to date the crystallisation age of igneous rocks. Monazite is commonly present as an accessory mineral in low-CaO peraluminous granitoids, from diorites, micaceous granites to pegmatites. The reason for the low CaO content is probably that melts with high CaO content promote the formation of apatite and allanite but not monazite. It is commonly formed from magmatism involving carbonatic melts but not mafic plutons or lavas. Those rocks usually host economic REE ore deposits, making monazite geochronology important in mining exploration. The simplest monazite zonation showing successive crystallisation of melts is concentric zonation, in which new monazite layers are crystallized rim-by-rim around the pre-existing core. The rims often show compositional variations due to the preferential incorporation of certain elements in the crystal lattice. For example, considering a closed system, Th is preferentially incorporated into the monazite mineral structure, leaving a Th-depleted melt. Therefore, older monazite near the core of a grain is rich in Th while younger monazite contains less, resulting in a rimward decrease of Th in a concentric zoning pattern. Investigating composition and age variation of these rims help to constrain the timing and rate of crystallisation as well as the composition of the melt, especially for rocks where zircon is not present.
Sources: en.wikipedia.org
==== Actions ==== RO5203648 binds to the mouse, rat, cynomolgus monkey, and human TAAR1 all with high affinity (Ki = 0.5–6.8 nM). It is a potent partial agonist in all species (EC50Tooltip half-maximal effective concentration = 4.0 to 31 nM), with an efficacy of 48 to 73% relative to the endogenous TAAR1 agonists β-phenethylamine and tyramine and the TAAR1 full agonist RO5166017. RO5203648 is highly selective for the TAAR1, showing ≥130-fold selectivity for the mouse TAAR1 over 149 other targets.
Hence, even though nihonium is in group 13, it has several properties similar to the group 17 elements. (Tennessine in group 17 has some group-13-like properties, as it has three valence electrons outside the 7s2 7p2 closed shell.) Nihonium is expected to be able to gain an electron to attain this closed-shell configuration, forming the −1 oxidation state like the halogens (fluorine, chlorine, bromine, iodine, and astatine). This state should be more stable than it is for thallium as the SO splitting of the 7p subshell is greater than that for the 6p subshell. Nihonium should be the most electronegative of the metallic group 13 elements, even more electronegative than tennessine, the period 7 congener of the halogens: in the compound NhTs, the negative charge is expected to be on the nihonium atom rather than the tennessine atom. The −1 oxidation should be more stable for nihonium than for tennessine. The electron affinity of nihonium is calculated to be around 0.68 eV, higher than thallium's at 0.4 eV; tennessine's is expected to be 1.8 eV, the lowest in its group. It is theoretically predicted that nihonium should have an enthalpy of sublimation around 150 kJ/mol and an enthalpy of adsorption on a gold surface around −159 kJ/mol.
== Menu and advertising == The first Taco Bell commercials premiered in 1968, featuring advertisements with Mel Blanc, Pat Harrington, and the then-host of Truth or Consequences, Bob Barker. In 1992, Johnny Cash starred in a television commercial for Taco Bell's value menu. In 1993, Taco Bell was used as product placement and plot device in the movie Demolition Man updating their currently used logo. From August 1997 to July 2000, Gidget the Chihuahua was the brand's advertising mascot, a campaign developed by TBWA. Voiced by Carlos Alazraqui, slogans included “¡Yo quiero Taco Bell!” (I want Taco Bell!), “Drop the Chalupa,” and “¡Viva Gorditas!” All became catchphrases in popular culture. In 2000, Taco Bell: Tasty Temple Challenge was released for DOS by Taco Bell as the publisher and developed by BrandGames as a kid-friendly first-person 3D action shooter with gameplay similar to that of Doom and Wolfenstein 3D in terms of combat and exploration, serving as an advertisement for the brand. The player controls Baja Bill, who explores a temple of a lost jungle civilization, battling snakes and scorpions with Taco Bell's hot and wild sauce. Food from the brand also appears in game and is used to replenish the protagonist's health.
== The TRAIL receptors as a drug target == In clinical trials only a small proportion of cancer patients responded to various drugs that targeted TRAIL death receptors. Many cancer cell lines develop resistance to TRAIL and limits the efficacy of TRAIL-based therapies.
Sources: en.wikipedia.org
==== Iraq War ==== Hitchens employed the term "Islamofascist" and supported the Iraq War, causing his critics to consider him a "neoconservative". Hitchens, however, refused to embrace this designation, insisting, "I'm not any kind of conservative". In 2004, Hitchens stated that neoconservative support for US intervention in Iraq convinced him that he was "on the same side as the neo-conservatives" when it came to contemporary foreign policy issues, and characterized himself as an unqualified "supporter of Paul Wolfowitz." He referred to his associations as "temporary neocon allies". In this period he opined that "the Bush administration [...] has redefined the lazy term 'conservative' to mean someone who is impatient with the status quo." In the years after the fatwa issued against Salman Rushdie in response to his novel The Satanic Verses, Hitchens became increasingly critical of what he called "excuse making" on the left. At the same time, he was attracted to the foreign policy ideas of some on the Republican-right that promoted pro-liberalism intervention, especially the neoconservative group that included Paul Wolfowitz. Around this time, he befriended the Iraqi dissident and businessman Ahmed Chalabi. Hitchens argued the case for the Iraq War in a 2003 collection of essays entitled A Long Short War: The Postponed Liberation of Iraq, and participated in public debates on the topic with George Galloway, Scott Ritter, and his brother Peter Hitchens.
== Risks == The risk of complications of the surgical wound is greater for those greater than 65-years-old, or who have pulmonary disease, nutritional deficiencies, overweight, other illnesses and high blood pressure.
Gerald (Jerry) Ledlow, Dean of UT Health Science Center at Tyler School of Community and Rural Health; Erich Heneke, Director of Business Integrity Continuity in Mayo Clinic's Supply Chain Management (SCM); Mike Loughrin, President of Transformance Advisors; Renata Rieder, Head of Service Management at Federal Office of Information Technology, Systems and Telecommunication for the Government of Switzerland; David Jacoby, President of Boston Strategies International; and Jorge A. Morales, former RFID technology advisor to the Mexican Government.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.